VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ T2DM as defined by American Diabetes Association   │ T2DM as defined by American Diabetes Association   │     100 │
│ (ADA) criteria                                     │ (ADA) criteria                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Adult patients with T2DM who are indicated to      │ Adult patients with T2DM who are indicated to      │     100 │
│ receive liraglutide, not as first-line therapy, in │ receive liraglutide, not as first-line therapy, in │         │
│ addition to diet and exercise to improve glycemic  │ addition to diet and exercise to improve glycemic  │         │
│ control                                            │ control                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically and angiographically stable CAD who     │ Clinically and angiographically stable CAD who     │     100 │
│ requires CABG as part of the standard medical      │ requires CABG as part of the standard medical      │         │
│ care, as CAD does not represent a contraindication │ care, as CAD does not represent a contraindication │         │
│ for using liraglutide. The stability of the CAD    │ for using liraglutide. The stability of the CAD    │         │
│ further warranties that study patients will not be │ further warranties that study patients will not be │         │
│ exposed to higher risk by using liraglutide        │ exposed to higher risk by using liraglutide        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a personal or family history of      │ Patients with a personal or family history of      │     100 │
│ medullary thyroid carcinoma or patients with       │ medullary thyroid carcinoma or patients with       │         │
│ Multiple Endocrine Neoplasia syndrome type 2       │ Multiple Endocrine Neoplasia syndrome type 2       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a prior serious hypersensitivity     │ Patients with a prior serious hypersensitivity     │     100 │
│ reaction to liraglutide                            │ reaction to liraglutide                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other contra-indications to liraglutide in         │ Other contra-indications to liraglutide in         │     100 │
│ accordance with risks and safety information       │ accordance with risks and safety information       │         │
│ included in the latest updated prescribing         │ included in the latest updated prescribing         │         │
│ information                                        │ information                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Type 1 diabetes, as defined by ADA criteria        │ Type 1 diabetes, as defined by ADA criteria        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of other GLP-1A, dipeptidyl peptidase  │ Current use of other GLP-1A, dipeptidyl peptidase  │     100 │
│ 4 (DPP4) or Sodium Glucose transporters 2 (SGLT2)  │ 4 (DPP4) or Sodium Glucose transporters 2 (SGLT2)  │         │
│ inhibitors, thiazolidinediones (TZDs), pramlintide │ inhibitors, thiazolidinediones (TZDs), pramlintide │         │
│ and fixed prandial insulin                         │ and fixed prandial insulin                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with unstable CAD, assessed by the        │ Patients with unstable CAD, assessed by the        │     100 │
│ Cardiology team and defined as new onset angina,   │ Cardiology team and defined as new onset angina,   │         │
│ rest angina, rapidly increasing or crescendo       │ rest angina, rapidly increasing or crescendo       │         │
│ angina                                             │ angina                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of diabetic ketoacidosis, pancreas or      │ History of diabetic ketoacidosis, pancreas or      │     100 │
│ beta-cell transplantation, or diabetes secondary   │ beta-cell transplantation, or diabetes secondary   │         │
│ to pancreatitis or pancreatectomy; acute or        │ to pancreatitis or pancreatectomy; acute or        │         │
│ chronic infective diseases, cancer or              │ chronic infective diseases, cancer or              │         │
│ chemotherapy, history of pulmonary, renal or liver │ chemotherapy, history of pulmonary, renal or liver │         │
│ diseases, and drug abuse                           │ diseases, and drug abuse                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with chronic and acute inflammatory       │ Patients with chronic and acute inflammatory       │     100 │
│ conditions such as sepsis, rheumatoid arthritis,   │ conditions such as sepsis, rheumatoid arthritis,   │         │
│ ectopic dermatitis, asthma, ulcerative colitis     │ ectopic dermatitis, asthma, ulcerative colitis     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of systemic corticosteroids in the 3   │ Current use of systemic corticosteroids in the 3   │     100 │
│ months prior this study                            │ months prior this study                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or breast-feeding women                   │ Pregnant or breast-feeding women                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females of childbearing potential who are not      │ Females of childbearing potential who are not      │     100 │
│ using adequate contraceptive methods (as required  │ using adequate contraceptive methods (as required  │         │
│ by local law or practice)                          │ by local law or practice)                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age ≥ 18 years old                                 │ Age = 18 years old                                 │      94 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin A1c (HbA1c) ≤ 9%                        │ Hemoglobin A1c (HbA1c) = 9%                        │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Body mass index (BMI) ≥ 27 Kg/m2 and/or waist      │ Body mass index (BMI) = 27 Kg/m2 and/or waist      │      98 │
│ circumference ≥ 102 cm (40 inches) in men and 88   │ circumference = 102 cm (40 inches) in men and 88   │         │
│ cm (35 inches) in women, respectively              │ cm (35 inches) in women, respectively              │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria      │   Score │
╞═══════════════════════════════════╪════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Age = 18 years old │      43 │
╘═══════════════════════════════════╧════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 96.16666666666667
OverAll Ratio: 97.58333333333334
